FBIO · Fortress Biotech, Inc.

0001104659-26-061233

Summary

Fortress Biotech swung to $110.4M net income and $2.82 diluted EPS in Q1 2026 from prior-year losses, driven by strong operating cash generation of $203.9M despite ongoing operating loss, reflecting non-operating gains and cost efficiencies.

Key takeaways

Revenue increased 22.1% to $16.0M from $13.1M as product sales grew despite competitive pressures on legacy products like Accutane and foam franchise.
Gross profit rose 17.6% to $9.8M, maintaining 61.2% gross margin amid shifts in product mix.
Operating loss narrowed 65.3% to -$7.7M from -$22.3M due to lower stock-based compensation and R&D expenses from prior grant vestings.
Net income achieved $110.4M profit versus -$10.6M loss, with diluted EPS of $2.82 versus -$0.48, propelled by significant non-operating factors.

Full analysis

Looking forward, the company acknowledges a history of operating losses expected to continue, with uncertainty around sustaining revenues or achieving profitability. Capital needs persist for infrastructure to support anticipated growth, maintaining investor focus on cash deployment efficiency amid biotech volatility.